AtaiBeckley (ATAI) Receivables - Accured (2023 - 2025)

AtaiBeckley (ATAI) reported Receivables - Accured of $10.2 million for Q3 2025, up 20300.0% sequentially from $50000.0 in Q4 2023.

AtaiBeckley (ATAI) Receivables - Accured (2023 - 2025) Analysis & Trends

AtaiBeckley (ATAI) has 2 years of Receivables - Accured data on file, last reported at $10.2 million in Q3 2025.

For the quarter ending Q3 2025, Receivables - Accured changed N/A year-over-year to $10.2 million; the trailing twelve-month figure through Sep 2025 stood at $10.2 million (changed N/A YoY), and the FY2023 full-year result was $50000.0, changed N/A from the prior year.
Receivables - Accured climbed to $10.2 million in Q3 2025, from $50000.0 in the prior quarter.
In the past five years, Receivables - Accured ranged from a high of $10.2 million in Q3 2025 to a low of $50000.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables - Accured (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	AtaiBeckley	2.56 Bn	2.56 Bn	-	10.20 Mn

Download Data